Frexalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | CD40 ligand |
| Clinical data | |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
| KEGG |
|
Frexalimab is an second-generation monoclonal antibody[1] for the treatment of relapsing multiple sclerosis, under developement by Sanofi.[2]
Mechanism of action
See also
References
Demyelinating diseases of the central nervous system | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Signs and symptoms | |||||||||
| Investigations and diagnosis | |||||||||
| Approved treatment | |||||||||
| Other treatments | |||||||||
| Demyelinating diseases |
| ||||||||
| Other | |||||||||
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted | |||||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.